Pulmatrix (PULM) Total Non-Current Liabilities (2014 - 2025)

Pulmatrix (PULM) posted Total Non-Current Liabilities of $903000.0 for Q1 2025, down 2.8% sequentially from $929000.0 in Q4 2024.

Pulmatrix (PULM) Total Non-Current Liabilities (2014 - 2025) Analysis & Trends

Pulmatrix has reported Total Non-Current Liabilities for 7 years, with the latest figure at $903000.0 in Q1 2025.

Quarterly Total Non-Current Liabilities changed N/A year-over-year to $903000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $903000.0 (changed N/A YoY) and the FY2024 annual result came in at $929000.0, changed N/A from the prior year.
Total Non-Current Liabilities eased to $903000.0 in Q1 2025 per PULM's latest filing, from $929000.0 in the prior quarter.
Over five years, Total Non-Current Liabilities peaked at $929000.0 in Q4 2024 and troughed at $903000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Non-Current Liabilities (Qtr)
1	Vertex Pharmaceuticals	139.20 Bn	131.35 Bn	2.84 Bn	5.92 Bn
2	Regeneron Pharmaceuticals	86.09 Bn	78.10 Bn	3.93 Bn	7.74 Bn
3	Argenx Se	65.25 Bn	60.07 Bn	1.37 Bn	40.00 Mn
4	Moderna	59.04 Bn	53.90 Bn	52.00 Mn	3.92 Bn
5	BeOne Medicines	42.04 Bn	36.94 Bn	1.53 Bn	1.88 Bn
6	Alnylam Pharmaceuticals	31.61 Bn	28.30 Bn	992.69 Mn	4.20 Bn
7	BioNTech SE	28.04 Bn	9.65 Bn	668.28 Mn	724.15 Mn
8	Insmed	27.50 Bn	26.33 Bn	358.27 Mn	1.17 Bn
9	Royalty Pharma	27.34 Bn	26.50 Bn	-	9.32 Bn
10	Pulmatrix	5.55 Mn	5.55 Mn	-	-

Download Data